CY1125052T1 - Κρυσταλλικες μορφες - Google Patents

Κρυσταλλικες μορφες

Info

Publication number
CY1125052T1
CY1125052T1 CY20221100195T CY221100195T CY1125052T1 CY 1125052 T1 CY1125052 T1 CY 1125052T1 CY 20221100195 T CY20221100195 T CY 20221100195T CY 221100195 T CY221100195 T CY 221100195T CY 1125052 T1 CY1125052 T1 CY 1125052T1
Authority
CY
Cyprus
Prior art keywords
crystal forms
pharmaceutical compositions
crystalline forms
crystalline
phosphono
Prior art date
Application number
CY20221100195T
Other languages
Greek (el)
English (en)
Inventor
Daniel Leuenberger
Stefan Reber
Markus Von Raumer
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of CY1125052T1 publication Critical patent/CY1125052T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CY20221100195T 2016-09-22 2022-03-09 Κρυσταλλικες μορφες CY1125052T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2016072562 2016-09-22
PCT/EP2017/073858 WO2018055016A1 (en) 2016-09-22 2017-09-21 Crystalline forms

Publications (1)

Publication Number Publication Date
CY1125052T1 true CY1125052T1 (el) 2024-02-16

Family

ID=59923448

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20221100195T CY1125052T1 (el) 2016-09-22 2022-03-09 Κρυσταλλικες μορφες

Country Status (27)

Country Link
US (4) US10730896B2 (enExample)
EP (2) EP3515924B1 (enExample)
JP (1) JP7097369B2 (enExample)
KR (1) KR102552795B1 (enExample)
CN (1) CN109715639B (enExample)
AU (1) AU2017331930B2 (enExample)
CA (1) CA3037794A1 (enExample)
CL (1) CL2019000728A1 (enExample)
CY (1) CY1125052T1 (enExample)
DK (1) DK3515924T3 (enExample)
EA (1) EA201990723A1 (enExample)
ES (1) ES2908572T3 (enExample)
HR (1) HRP20220234T1 (enExample)
HU (1) HUE057772T2 (enExample)
IL (1) IL265445B2 (enExample)
LT (1) LT3515924T (enExample)
MA (1) MA46266B1 (enExample)
MX (1) MX381590B (enExample)
MY (1) MY193080A (enExample)
PH (1) PH12019500567B1 (enExample)
PL (1) PL3515924T3 (enExample)
PT (1) PT3515924T (enExample)
RS (1) RS62946B1 (enExample)
SI (1) SI3515924T1 (enExample)
TW (1) TWI752086B (enExample)
UA (1) UA124073C2 (enExample)
WO (1) WO2018055016A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109715639B (zh) 2016-09-22 2022-04-19 爱杜西亚药品有限公司 结晶形式
SG11201908128YA (en) 2017-03-15 2019-10-30 Idorsia Pharmaceuticals Ltd Subcutaneous administration of a p2y12 receptor antagonist
TWI905227B (zh) 2020-07-15 2025-11-21 新加坡商暉致亞太私人有限公司 包含p2y12受體拮抗劑的水性醫藥組合物
CA3223733A1 (en) 2021-07-13 2023-01-19 Nicole Blumer A process for the synthesis of 4-((r)-2-{[6-((s)-3-methoxy-pyrrolidin-1-yl)-2-phenyl- pyrimidine-4-carbonyl]-amino}-3-phosphono-propionyl)-piperazine-1 -carboxylic acid butyl ester

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5373586A (en) 1976-12-09 1978-06-30 Mitsubishi Chem Ind Ltd New penicillin derivatives
CA2020437A1 (en) 1989-07-05 1991-01-06 Yoshihide Fuse Cinnamamide derivative
CA2375920A1 (en) 1999-06-14 2000-12-21 Eli Lilly And Company Compounds
US6861424B2 (en) 2001-06-06 2005-03-01 Schering Aktiengesellschaft Platelet adenosine diphosphate receptor antagonists
CN1747732A (zh) 2002-12-11 2006-03-15 舍林股份公司 作为血小板腺苷二磷酸受体拮抗剂的2-氨基羰基喹啉化合物
WO2004092189A1 (en) 2003-04-09 2004-10-28 Wyeth Derivatives of 2-(8,9-dioxo-2,6-diazabicyclo(5.2.0)non-1(7)-en-2-yl)alkyl phosphonic acid and their use as n-methyl-d-aspartate (nmda) recetor antagonists
TW200640877A (en) 2005-04-28 2006-12-01 Actelion Pharmaceuticals Ltd Pyrimidine derivatives
ES2421448T3 (es) 2005-10-21 2013-09-02 Actelion Pharmaceuticals Ltd Derivados de piperazina como agentes contra la malaria
CL2007002920A1 (es) 2006-10-13 2008-06-06 Actelion Pharmaceuticals Ltd Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos.
AR063518A1 (es) 2006-10-25 2009-01-28 Actelion Pharmaceuticals Ltd Derivados 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y su uso para tratar y/o prevenir enfermedades vasculares perifericas viscerales, hepaticas y renales, enfermedades cardiovasculares y enfermedades cerebrovasculares asociados con la agregacion de plaquetas, incluyendo trombosis
JP4785881B2 (ja) 2007-02-27 2011-10-05 大塚製薬株式会社 医薬
CA2684644A1 (en) 2007-04-23 2008-10-30 Sanofi-Aventis Quinoline-carboxamide derivatives as p2y12 antagonists
RU2483072C2 (ru) 2007-11-29 2013-05-27 Актелион Фармасьютиклз Лтд Производные фосфоновой кислоты и их применение в качестве антагонистов рецептора p2y12
EP2238127B1 (en) 2007-12-26 2012-08-15 Sanofi Pyrazole-carboxamide derivatives as p2y12 antagonists
EP2238128B1 (en) 2007-12-26 2012-08-22 Sanofi Heterocyclic pyrazole-carboxamides as p2y12 antagonists
AR071653A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2-fenil-4-ciclopropil-pirimidina
AR071652A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2- fenil-piridina substituidos
MX2011010200A (es) 2009-04-08 2011-10-14 Actelion Pharmaceuticals Ltd 6-(3-aza-biciclo[3.1.0]hex-3-il)-2fenil-pirimidinas como antagonistas del receptor de adenosina 5'-difosfato (adp).
JP5536876B2 (ja) 2009-04-22 2014-07-02 アクテリオン ファーマシューティカルズ リミテッド チアゾール誘導体及びp2y12受容体拮抗剤としてのそれらの使用
CN109715639B (zh) 2016-09-22 2022-04-19 爱杜西亚药品有限公司 结晶形式
SG11201908128YA (en) 2017-03-15 2019-10-30 Idorsia Pharmaceuticals Ltd Subcutaneous administration of a p2y12 receptor antagonist
TWI905227B (zh) 2020-07-15 2025-11-21 新加坡商暉致亞太私人有限公司 包含p2y12受體拮抗劑的水性醫藥組合物

Also Published As

Publication number Publication date
CL2019000728A1 (es) 2019-07-05
US10730896B2 (en) 2020-08-04
PL3515924T3 (pl) 2022-04-11
DK3515924T3 (da) 2022-03-21
NZ750772A (en) 2023-10-27
IL265445B2 (en) 2024-05-01
UA124073C2 (uk) 2021-07-14
US20200017534A1 (en) 2020-01-16
TW201813965A (zh) 2018-04-16
US12227532B2 (en) 2025-02-18
AU2017331930A1 (en) 2019-03-07
HUE057772T2 (hu) 2022-06-28
EP3515924A1 (en) 2019-07-31
MX381590B (es) 2025-03-12
EP3515924B1 (en) 2021-12-15
IL265445B1 (en) 2024-01-01
JP2019529553A (ja) 2019-10-17
MA46266A (fr) 2019-07-31
US20210009614A1 (en) 2021-01-14
TWI752086B (zh) 2022-01-11
SI3515924T1 (sl) 2022-04-29
WO2018055016A1 (en) 2018-03-29
EP3981774A1 (en) 2022-04-13
US11365209B2 (en) 2022-06-21
US20250163086A1 (en) 2025-05-22
KR20190052704A (ko) 2019-05-16
PH12019500567B1 (en) 2024-01-31
US20220275011A1 (en) 2022-09-01
JP7097369B2 (ja) 2022-07-07
EA201990723A1 (ru) 2019-10-31
ES2908572T3 (es) 2022-05-03
MX2019003093A (es) 2019-07-18
PH12019500567A1 (en) 2019-11-18
RS62946B1 (sr) 2022-03-31
LT3515924T (lt) 2022-03-10
KR102552795B1 (ko) 2023-07-06
BR112019004845A2 (pt) 2019-06-04
HRP20220234T1 (hr) 2022-05-13
AU2017331930B2 (en) 2021-07-15
IL265445A (en) 2019-05-30
PT3515924T (pt) 2022-03-11
CN109715639B (zh) 2022-04-19
CA3037794A1 (en) 2018-03-29
MA46266B1 (fr) 2022-02-28
MY193080A (en) 2022-09-26
CN109715639A (zh) 2019-05-03

Similar Documents

Publication Publication Date Title
CY1124726T1 (el) Παραγωγα κιναζολινης που χρησιμοποιουνται για την αντιμετωπιση του hiv
CY1124855T1 (el) 2-(μορφολιν-4-υλ)-1,7-ναφθυριδινες
CY1124848T1 (el) Φαρμακευτικες συνθεσεις που περιλαμβανουν azd9291
CY1125359T1 (el) Νεα υποκατεστημενα με 6-6 δικυκλικο αρωματικο δακτυλιο νουκλεοσιδικα αναλογα για χρηση ως αναστολεις prmt5
MX391812B (es) Agonista fxr derivado de esteroides.
BR112017013491A2 (pt) compostos de pirimidina fundida para o tratamento de hiv
JOP20220305A1 (ar) ستيرويد 19- نور c3، 3- به استبدال ثنائي لـ c21-n بيرازوليل بلوري
CY1123479T1 (el) Θετικοι αλλοστερικοι διαμορφωτες μουσκαρινικου υποδοχεα μ1
EA201990388A1 (ru) Пиперидиновые модуляторы рецепторов cxcr7
BR112018005497A2 (pt) compostos heterocíclicos e usos dos mesmos
EA201892007A1 (ru) 3-дезоксипроизводное и фармацевтические композиции на его основе
EA201790389A1 (ru) Пирролопиримидиновые соединения, используемые в качестве агониста tlr7
EA201690848A1 (ru) Производные бициклического пиридила с конденсированными кольцами в качестве ингибиторов fgfr4
JO3430B1 (ar) مشتقات حمض أميني جديدة، عملية لتحضيرها وتركيبات صيدلية تحتوي عليها
CY1124251T1 (el) Παραγωγα καρβοξαμιδιου
MX381487B (es) Ciertos inhibidores de la proteina quinasa.
EA201591301A1 (ru) Новые пиримидиновые и пиридиновые соединения и их применение
EA201790337A1 (ru) Кристаллические формы ингибиторов глутаминазы
EA201790892A1 (ru) Кристаллические формы 5-хлор-n4-[2-(диметилфосфорил)фенил]-n2-{2-метокси-4-[4-(4-метилпиперазин-1-ил)пиперидин-1-ил]}пиримидин-2,4-диамина
MX380546B (es) Derivados de pirazolopirimidona o pirrolotriazona, metodo y preparacion de los mismos y aplicaciones farmaceuticas de los mismos.
CY1121596T1 (el) Αμιδια βενζοξαζινονης ως αλατοκορτικοειδεις ρυθμιστες υποδοχεα
EA201790275A1 (ru) Кристаллические формы 6-((6,7-диметоксихиназолин-4-ил)окси)-n,2-диметилбензофуран-3-карбоксамида
EA029499B9 (ru) Ингибиторы rorc2 и способы их применения
MX2017012295A (es) Derivados formilados n-heterociclicos como inhibidores de fgfr4.
EA201690390A1 (ru) Производные амидов в качестве антагонистов рецептора к лизофосфатидной кислоте